Factor analysis of the expanded prostate cancer index composite in a patient group after primary (external beam radiotherapy and permanent iodine-125 brachytherapy) and postoperative radiotherapy for prostate cancer

Current Urology

Volumn 2, Issue 3, 2009, Pages 122-129

  Volz Sidiropoulou, Eftychia ^a   Pinkawa, Michael ^a   Fischedick, Karin ^a   Jakse, Gerhard ^a   Gauggel, Siegfried ^a   Eble, Michael J ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Brachytherapy; Hormonal treatment; Prostate cancer; Prostatectomy; Quality of life; Radiotherapy

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FACTORIAL ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE INDEX;

EID: 77953374409     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000189652     Document Type: Article

References (22)

1. Speight JL, Roach M 3rd: Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions. J Clin Oncol 2005;23:8176-8185.
2. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000;56:899-905.
3. Wei JT, Dunn RL, Sandler HM, McLaughlin PW, Montie JE, Litwin MS, Nyquist L, Sanda MG: Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002;20:557-566.
4. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG: Neo-adjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy. Urology 2002;59:480-484.
5. Hollenbeck BK, Dunn RL, Wei JT, McLaughlin PW, Han M, Sanda MG: Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument. J Urol 2003;169:1453-1457.
6. Ash D, Bottomley D, Al-Qaisieh B, Carey B, Gould K, Henry A: A prospective analysis of long-term quality of life after permanent I-125 brachytherapy for localised prostate cancer. Radiother Oncol 2007;84:135-139.
7. Link RE, Su LM, Sullivan W, Bhayani SB, Pavlovich CP: Health related quality of life before and after laparoscopic radical prostatectomy. J Urol 2005;173:175-179.
8. Pinkawa M, Fischedick K, Treusacher P, Asadpour B, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ: Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer - a phase II study. Radiother Oncol 2006;78:41-46.
9. Pinkawa M, Fischedick K, Gagel B, Piroth MD, Borchers H, Jakse G, Eble MJ: Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer. Urology 2006;68:104-109.
10. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Eble MJ: Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Oncol Biol Phys 2006;64:835-841.
11. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Nussen S, Eble MJ: Toxicity profile with a large prostate volume after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:83-89.
12. Pinkawa M, Fischedick K, Asadpour B, Gagel B, Piroth MD, Holy R, Krenkel B, Eble MJ: Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis. Radiother Oncol 2008;88:135-139.
13. Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, Klotz J, Eble MJ: Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol 2009;55:227-236.
14. Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, Camphausen K, Coleman CN, Singh AK: Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score. Int J Radiat Oncol Biol Phys 2008;70:90-95.
15. Pinkawa M, Fischedick K, Maurer U, Borchers H, Jakse G, Eble MJ: Subacute and late toxicity after interstitial permanent, interstitial temporary and external irradiation of the prostate. Int J Radiat Oncol Biol Phys 2003; 57(suppl):S228-229.
16. Pinkawa M, Fischedick K, Piroth MD, Gagel B, Borchers H, Jakse G, Eble MJ: Health-related quality of life after permanent interstitial brachytherapy for prostate cancer - correlation with postimplant CT scan parameters. Strahlenther Onkol 2006;182:660-665.
17. Tabachnik BG, Fidell LS: Principal components and factor analysis. New York, Allyn and Bacon, 2007.
18. Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L: ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315-321.
19. Nag S, Beyer D, Friedland J, Grimm P, Nath R: American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799.
20. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-1261.
21. Wirth MP, Hakenberg OW, Froehner M: Antiandrogens in the treatment of prostate cancer. Eur Urol 2007;51:306-314.
22. Brenner DJ: Fractionation and late rectal toxicity. Int J Radiat Oncol Biol Phys 2004;60:1013-1015.